Istaroxime, a first in class new chemical entity exhibiting SERCA-2 activation and Na-K-ATPase inhibition: A new promising treatment for acute heart failure syndromes?

Heart Failure Reviews

Volumn 14, Issue 4, 2009, Pages 277-287

  Khan, Hashim ^a   Metra, Marco ^b   Blair, John E A ^a   Vogel, Mark ^a   Harinstein, Matthew E ^a   Filippatos, Gerasimos S ^c   Sabbah, Hani N ^d   Porchet, Herve ^e   Valentini, Giovanni ^f   Gheorghiade, Mihai ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF BRESCIA   (Italy)

^c NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^d HENRY FORD HOSPITAL   (United States)

^e DEBIOPHARM SA   (Switzerland)

^f Sigma Tau SpA   (Italy)

Author keywords

Acute heart failure; Hemodynamics; Lusitropy; Therapy

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); BRAIN NATRIURETIC PEPTIDE; DIGOXIN; ISOENZYME; ISTAROXIME; PLACEBO; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE;

ABDOMINAL PAIN; ACUTE HEART FAILURE; ANGINA PECTORIS; ARTHRALGIA; BACKACHE; BLOOD PRESSURE REGULATION; BRADYCARDIA; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTINUOUS INFUSION; DIARRHEA; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG FATALITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ENZYME ACTIVATION; ENZYME INHIBITION; GASTROINTESTINAL TOXICITY; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART CONTRACTION; HEART FAILURE; HEART LEFT BUNDLE BRANCH BLOCK; HEART MUSCLE CONDUCTION DISTURBANCE; HEART MUSCLE CONTRACTILITY; HEART MUSCLE ISCHEMIA; HEART MUSCLE RELAXATION; HEART RATE; HEART VENTRICLE EXTRASYSTOLE; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPOTENSION; INJECTION SITE INFLAMMATION; INJECTION SITE IRRITATION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; LABORATORY TEST; LEG ISCHEMIA; LIMB PAIN; LOW DRUG DOSE; LUNG EDEMA; MALAISE; MORBIDITY; MORTALITY; NAUSEA; NONHUMAN; PULMONARY ARTERY OCCLUSION PRESSURE; QT PROLONGATION; REVIEW; SIDE EFFECT; ST SEGMENT; SUDDEN DEATH; TACHYCARDIA; THORAX PAIN; TRANSIENT ISCHEMIC ATTACK; VASODILATATION; VOMITING;

ACUTE DISEASE; ANIMALS; CARDIOTONIC AGENTS; DOBUTAMINE; ETIOCHOLANOLONE; HEART FAILURE; HEMODYNAMICS; HUMANS; PULMONARY WEDGE PRESSURE; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES; SODIUM-POTASSIUM-EXCHANGING ATPASE;

EID: 70449090165     PISSN: 13824147     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10741-009-9136-z     Document Type: Review

References (25)

1. D Lloyd-Jones, et al. 2009 Heart disease and stroke statistics-2009 update. A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee Circulation 119 3 e21 e181 10.1161/ CIRCULATIONAHA.108.191261 10.1161/CIRCULATIONAHA.108.191261 19075105
2. DM Lloyd-Jones, et al. 2002 Lifetime risk for developing congestive heart failure: the Framingham Heart Study Circulation 106 24 3068 3072 10.1161/01.CIR.0000039105.49749.6F 10.1161/01.CIR.0000039105.49749.6F 12473553 (Pubitemid 35440290)
3. M Gheorghiade, et al. 2005 Acute heart failure syndromes: current state and framework for future research Circulation 112 25 3958 3968 10.1161/CIRCULATIONAHA.105.590091 10.1161/CIRCULATIONAHA.105.590091 16365214 (Pubitemid 43739494)
4. M Gheorghiade, et al. 2006 Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure J Am Med Assoc 296 18 2217 2226 10.1001/jama.296.18.2217 10.1001/jama.296.18. 2217 1:CAS:528:DC%2BD28XhtFKrtbzJ (Pubitemid 44708052)
5. U Elkayam, et al. 2007 Use and impact of inotropes and vasodilator therapy in hospitalized patients with severe heart failure Am Heart J 153 1 98 104 10.1016/j.ahj.2006.09.005 10.1016/j.ahj.2006.09.005 17174645 (Pubitemid 44880871)
6. AJ Burger, et al. 2002 Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the PRECEDENT study Am Heart J 144 6 1102 1108 10.1067/mhj.2002.125620 10.1067/mhj.2002.125620 1:CAS:528:DC%2BD3sXnvFWk 12486437 (Pubitemid 36026926)
7. S Thackray, et al. 2002 The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure-a meta-regression analysis Eur J Heart Fail 4 4 515 529 10.1016/S1388-9842(02)00041-7 10.1016/S1388-9842(02)00041-7 1:CAS:528: DC%2BD38XlvF2ru7o%3D 12167393 (Pubitemid 36564973)
8. M Packer, et al. 1991 Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group N Engl J Med 325 21 1468 1475 1:STN:280:DyaK38%2FkvFGlsQ%3D%3D 1944425
9. MS Cuffe, et al. 2002 Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial J Am Med Assoc 287 12 1541 1547 10.1001/jama.287.12.1541 10.1001/jama.287.12.1541 1:CAS:528:DC%2BD38XisVegt78%3D
10. GM Felker, et al. 2003 Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study J Am Coll Cardiol 41 6 997 1003 10.1016/S0735-1097(02)02968-6 10.1016/S0735-1097(02)02968- 6 1:CAS:528:DC%2BD3sXislejsLk%3D 12651048 (Pubitemid 36315544)
11. A Mebazaa, et al. 2007 Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial J Am Med Assoc 297 17 1883 1891 10.1001/jama.297.17.1883 10.1001/jama.297.17.1883 1:CAS:528:DC%2BD2sXkvFKrsLs%3D (Pubitemid 46707842)
12. JG Cleland, et al. 2006 Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE Eur J Heart Fail 8 1 105 110 10.1016/j.ejheart.2005.12.003 10.1016/j.ejheart. 2005.12.003 1:CAS:528:DC%2BD28XkvFWn 16387630 (Pubitemid 43012109)
13. GG Mattera, et al. 2007 Istaroxime: a new luso-inotropic agent for heart failure Am J Cardiol 99 2A 33A 40A 10.1016/j.amjcard.2006.09.004 10.1016/j.amjcard.2006.09.004 1:CAS:528:DC%2BD2sXntlKjtg%3D%3D 17239702 (Pubitemid 46096881)
14. R Micheletti, et al. 2002 Pharmacological profile of the novel inotropic agent (E, Z)-3-((2-aminoethoxy)imino)androstane-6, 17-dione hydrochloride (PST2744) J Pharmacol Exp Ther 303 2 592 600 10.1124/jpet.102.038331 10.1124/jpet.102.038331 1:CAS:528:DC%2BD38XotlCgu7s%3D 12388640 (Pubitemid 35231230)
15. HN Sabbah, et al. 2007 Hemodynamic properties of a new-generation positive luso-inotropic agent for the acute treatment of advanced heart failure Am J Cardiol 99 2A 41A 46A 10.1016/j.amjcard.2006.09.005 10.1016/j.amjcard.2006. 09.005 1:CAS:528:DC%2BD2sXntlKjtA%3D%3D 17239704 (Pubitemid 46096882)
16. JK Ghali, et al. 2007 A phase 1-2 dose-escalating study evaluating the safety and tolerability of istaroxime and specific effects on electrocardiographic and hemodynamic parameters in patients with chronic heart failure with reduced systolic function Am J Cardiol 99 2A 47A 56A 10.1016/j.amjcard.2006.09.006 10.1016/j.amjcard.2006.09.006 1:CAS:528: DC%2BD2sXntlKjtQ%3D%3D 17239705 (Pubitemid 46096883)
17. JE Blair, et al. 2008 Rationale and design of the hemodynamic, echocardiographic and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure (HORIZON-HF) trial Am J Ther 15 3 231 240 10.1097/MJT.0b013e31816d9186 10.1097/MJT.0b013e31816d9186 18496261
18. M Gheorghiade, et al. 2008 Hemodynamic, echocardiographic, and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure J Am Coll Cardiol 51 23 2276 2285 10.1016/j.jacc.2008.03.015 10.1016/j.jacc.2008.03.015 1:CAS:528:DC%2BD1cXmvVOgsLo%3D 18534276
19. WT Abraham, et al. 2005 In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE) J Am Coll Cardiol 46 1 57 64 10.1016/j.jacc.2005.03.051 10.1016/j.jacc.2005.03. 051 15992636 (Pubitemid 40905130)
20. G Hasenfuss, et al. 1992 Alteration of contractile function and excitation-contraction coupling in dilated cardiomyopathy Circ Res 70 6 1225 1232 1:STN:280:DyaK383kvVyltg%3D%3D 1576741
21. DM Bers 2008 Calcium cycling and signaling in cardiac myocytes Annu Rev Physiol 70 23 49 10.1146/annurev.physiol.70.113006.100455 10.1146/annurev. physiol.70.113006.100455 1:CAS:528:DC%2BD1cXkt1eqsbg%3D 17988210 (Pubitemid 351738170)
22. KF Frank, et al. 2003 Sarcoplasmic reticulum Ca2+ -ATPase modulates cardiac contraction and relaxation Cardiovasc Res 57 1 20 27 10.1016/S0008-6363(02)00694-6 10.1016/S0008-6363(02)00694-6 1:CAS:528: DC%2BD38XpslSlsro%3D 12504810 (Pubitemid 36009432)
23. DM Bers JW Bassani RA Bassani 1996 Na-Ca exchange and Ca fluxes during contraction and relaxation in mammalian ventricular muscle Ann N Y Acad Sci 779 430 442 10.1111/j.1749-6632.1996.tb44818.x 10.1111/j.1749-6632.1996.tb44818.x 1:CAS:528:DyaK28Xktlarur4%3D 8659859 (Pubitemid 26194677)
24. M Meyer, et al. 1995 Alterations of sarcoplasmic reticulum proteins in failing human dilated cardiomyopathy Circulation 92 4 778 784 1:CAS:528:DyaK2MXnsFGlsLk%3D 7641356
25. R Studer, et al. 1994 Gene expression of the cardiac Na(+)-Ca2+ exchanger in end-stage human heart failure Circ Res 75 3 443 453 1:CAS:528: DyaK2cXlsFClsLY%3D 8062418